$EVEREST MED(01952.HK) perhaps this is the most direct track for AI-driven drug discovery
Overview
EVEREST MED (1952)
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to ad...
- Open
- 26.000
- High
- 26.520
- Low
- 24.920
- Prev. Close
- 25.540
- Volume
- 5.26M
- Turnover
- 135.05M
- Avg Price
- 25.666
- Bid/Ask Ratio
- -33.33%
- Amplitude
- 6.26%
- 52wk High
- 50.300
- Volume Ratio
- 1.37
- Turnover Ratio
- 1.48%
- 52wk Low
- 22.700
- HK Mkt Cap
- 9.13B
- Market CapHKD
- 9.13B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.175
- EPSDynamic
- -0.0386
- EPSStatic
- --
- BVPS
- 16.98
- P/B
- 1.52
- HK Shares
- 354.64M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 354.64M
- Min lot size
- 500
- Currency
- HKD
EVEREST MED Analyst Rating
View moreForecast & Rating
Nov 2, 2026- Strong buy50.00%
- Buy0.00%
- Hold50.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 3
- Buy
- 0
- Hold
- 3
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Everest Medicines (1952.HK) experienced a choppy session on Nov 16, with the stock opening at HKD 25.96, rallying to an intraday high of HKD 26.40 in the morning session before retreating into the afternoon, closing at HKD 25.74 near the day's low, down 0.85% from open and reflecting profit-taking pressure after prior strength. BOCOM maintained its Buy rating, with market consensus suggesting upside potential exists. Product support came from regulatory approval—China greenlit a new 100 mg formulation of XERAVA for treating adult complicated intra-abdominal infections, expanding the drug's clinical application scope. The earnings profile reflects dual-track progress typical of early-stage biopharma: Q2 revenues surged 171% year-over-year to HKD 663 million, while the net loss of HKD 3.4 million contracted 97% versus prior year, demonstrating concurrent revenue scaling and loss-margin compression through the commercialization phase.
- Nov, 13
Everest Medicines fell 2.7% to HK$25.54 on profit-taking and persistent unprofitability. The stock is down 32.61% year-to-date and 49% from its 52-week high of HK$50.30, trading below MA20 and MA60. Q2 revenue surged 171% to HK$663 million, yet the company lost HK$34.3 million with a -51.78% margin. Recent catalysts—China's XERAVA 100mg approval and the Hasten partnership—have provided limited support as investors doubt the path to profitability.
- Nov, 12
Everest Medicines closed down approximately 2.4% to HK$26.24, extending the stock's ongoing downward trajectory that has now erased 47.83% from its 52-week high of HK$50.30 and marked a year-to-date decline of 30.77%, with the price trading well below both its 20-day and 60-day moving averages. While Q2 and Q1 revenues reached HK$662.9 million and HK$652.4 million respectively, demonstrating robust year-over-year growth of 171.52% and 173.08% respectively, persistent and deepening losses remain the primary headwind for the stock—both recent quarters posted negative earnings per share (Q2: -0.0116 HKD, Q1: -0.0114 HKD), with a net profit margin locked at -51.78%, showing the company remains far from profitability. Since August, the stock has endured repeated bouts of volatility stemming from the company's mRNA strategy pivot and broader US-China biotech policy shifts, and while recent strategic cooperation approvals represent a constructive step, they have proven insufficient to alleviate market concerns about the timeline for profitability recovery.
- Nov, 11
Everest Medicines fell 0.81% to close at HK$26.88, declining 29% year-to-date from HK$37.9 at the start of 2026. The stock has retreated 47.5% from its 52-week high of HK$51.2 reached in early November 2025, but has rebounded 18.4% from its 52-week low of HK$22.7 in late June, and currently trades below both the 20-day moving average of HK$29.27 and 60-day moving average of HK$29.91. Despite recent strength in operations, Q2 revenue reached HK$662.9 million with year-over-year growth of 171.5% and Q1 showed 173.1% growth, the company remains unprofitable, posting a Q2 net loss of HK$3.43 million. The company is advancing its mRNA strategy, having hired former Moderna executives and secured a strategic cooperation agreement with Hasten, while most brokers rate the stock as buy. Today's slight retreat may reflect profit-taking after recent optimism, while US-China biotech policy uncertainty and the company's near-term profitability challenges remain key headwinds.
- Nov, 10
Everest Medicines climbed 3.5% to HKD 27.10 today, reflecting positive market reception to its recent strategic developments. The company is advancing a strategic cooperation agreement with Hasten and has secured shareholder approval for an extraordinary general meeting to formalize the arrangement, while simultaneously hiring ex-Moderna executives to strengthen its mRNA vaccine pipeline. This dual-track approach underscores management's commitment to advancing innovation and commercialization readiness. Q2 financial results revealed revenues of HKD 662.9 million, surging 171.5% year-over-year and demonstrating significant commercial traction; the company is still in a net loss position at HKD 3.4 million for Q2, though the loss margin has narrowed by 98% compared to the prior year, indicating meaningful cost discipline during the commercialization phase. However, the stock's price positioning suggests cautious market sentiment persists—down 28.5% year-to-date and trading 47% below the 52-week high of HKD 51.20 recorded in November 2025, currently below its 60-day moving average of HKD 29.95.
News
TradingView · Everest Medicines Adds Two Drugs to China's Reimbursement List
PUBT · Everest Medicines Holds Extraordinary General Meeting
Weekly Review · Weekly Recap | EVEREST MED -2.44%, consensus target above spot
Tip Ranks · BOCOM International Holdings Company Sticks to Their Buy Rating for Everest Medicines Ltd. (1952)
Simplywall · What Investors Overlooked Before Everest Medicines Slid
Tip Ranks · China Approves New 100 mg XERAVA® Strength for Adult cIAI
Posts
View more- H
Hot trades in Hong Kong stocks (7.29)|Xiaomi's stock price hits a 1-month low, while innovative drug concepts buck the trend and rise!
The three major Hong Kong stock indices collectively retreated. WuXi AppTec's performance ignited the CRO sector, while tech stocks faced pressure, dragging down the indices.
